posaconazole
Commercial- Indications
- Fungal infections
Company intelligence / Profile preview
Sinotherapeutics Inc. specializes in the research & development, registration, manufacture, and commercialization of complex generic pharmaceuticals as well as innovative formulation products. The company has successfully developed China's first domestic generic posaconazole delayed-release tablet. It provides one-stop CRO/CDMO services covering all stages from pre-clinical to commercial production with a strong track record of regulatory compliance (FDA/NMPA audits). Its expertise lies in solving technical challenges related to water-insoluble drugs, sustained/controlled release systems, fixed-dose combinations, and topical formulations.
4 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sinotherapeutics Inc..